Over the last several years, an increasing body of evidence points to dysfunctional copper homeostasis in the pathogenesis of Alzheimer's. Recently, a published study demonstrated that consuming a vitamin containing copper supplement taken together with a high saturated and trans fat diet resulted in an equivalent of 19 years of mental decline.
A separate European clinical study correlated the levels of the highly reactive “free copper” pool in serum to disease severity in Alzheimer's patients versus aged-matched control patients. These results demonstrated that the “free copper” serum pool was highly increased in this patient population.
“The peer review process and receipt of this NIH grant provides us with additional confidence in the science of our approach of using an Coprexa, an agent which is capable of selectively lowering the levels of free copper in the brains of patients with copper-implicated neurodegenerative diseases, such as neurologically presenting Wilson's disease and possibly Alzheimer's disease,” commented Dr George Brewer, Emeritus Professor of Human Genetics at the University of Michigan.